JAZZ vs. IONS, MRTX, RARE, ARWR, RPRX, PRGO, CORT, SUPN, PCRX, and NKTR
Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Royalty Pharma (RPRX), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceutical preparations" industry.
Ionis Pharmaceuticals (NASDAQ:IONS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
Jazz Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 8 mentions for Ionis Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.87 beat Ionis Pharmaceuticals' score of 0.45 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.
Jazz Pharmaceuticals received 420 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 80.56% of users gave Jazz Pharmaceuticals an outperform vote while only 60.16% of users gave Ionis Pharmaceuticals an outperform vote.
Ionis Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Ionis Pharmaceuticals currently has a consensus price target of $59.54, suggesting a potential upside of 58.47%. Jazz Pharmaceuticals has a consensus price target of $192.75, suggesting a potential upside of 83.14%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Ionis Pharmaceuticals.
93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Jazz Pharmaceuticals' net margin of -49.49%. Ionis Pharmaceuticals' return on equity of 27.86% beat Jazz Pharmaceuticals' return on equity.
Summary
Jazz Pharmaceuticals beats Ionis Pharmaceuticals on 15 of the 19 factors compared between the two stocks.
Get Jazz Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jazz Pharmaceuticals Competitors List
Related Companies and Tools
